Abstract 313P
Background
Germ cell tumors (GCTs) are a prevalent malignancy among AYAs. The advent of multimodality treatment, including surgery, chemotherapy, and irradiation, has significantly improved outcomes, increasing the population of survivors. Surveillance highlights challenges related to late complications across physical, psychosocial, and work-related domains.
Methods
This retrospective analysis includes 66 GCT patients treated between 2010 and 2019, all of whom achieved a CR post first-line chemotherapy and were subsequently monitored through surveillance. CR was defined by normalization of tumor markers AFP and β-hCG and absence of any residual mass exceeding 1 cm in the long axis. Kaplan-Meier methods were used to evaluate progression-free survival (PFS) and overall survival (OS).
Results
All 66 patients achieved a CR and were managed under surveillance protocols. The median follow-up was 14.43 years, with the mean age at diagnosis being 20.2 years (range 7-52). Primary tumor sites included the testis (21%), extragonadal locations (16%), and the central nervous system (62%). IGCCCG risk classification included favorable (15.2%), intermediate (60.6%), and poor (24.2%). Treatment modalities included chemotherapy (100%) and radiotherapy (65%). Recurrence occurred in 15.1% of patients, with 5-year and 10-year disease-free survival (DFS) rates of 89.4% and 85.5%, respectively. One patient was diagnosed with secondary papillary thyroid cancer. At the last follow-up, the survival rate was 100%. Lifestyle and socioeconomic assessments showed an increase in overweight patients from 16.4% at diagnosis to 38.8% during surveillance. Additionally, 16.6% reported smoking, and 10.6% reported alcohol consumption post-treatment. 25.8% of survivors were not employed at the time of the survey, 93.9% remained unmarried, and only 1.53% had children.
Conclusions
This study highlights an excellent disease-free survival rate for GCT patients who achieved a CR post first-line chemotherapy. The findings underscore the impact of GCTs and their treatment on survivors' life and career decisions, emphasizing the need for comprehensive post-treatment support.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.